158 related articles for article (PubMed ID: 18676864)
1. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Naresh A; Thor AD; Edgerton SM; Torkko KC; Kumar R; Jones FE
Cancer Res; 2008 Aug; 68(15):6387-95. PubMed ID: 18676864
[TBL] [Abstract][Full Text] [Related]
2. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
[TBL] [Abstract][Full Text] [Related]
3. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
Rokicki J; Das PM; Giltnane JM; Wansbury O; Rimm DL; Howard BA; Jones FE
Mol Cancer; 2010 Jun; 9():150. PubMed ID: 20550710
[TBL] [Abstract][Full Text] [Related]
4. HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.
Han W; Jones FE
Biochem Biophys Res Commun; 2014 Jan; 443(2):458-63. PubMed ID: 24333426
[TBL] [Abstract][Full Text] [Related]
5. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.
Jones FE
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):247-58. PubMed ID: 18473151
[TBL] [Abstract][Full Text] [Related]
6. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
Thor AD; Edgerton SM; Jones FE
Am J Pathol; 2009 Nov; 175(5):1802-9. PubMed ID: 19808643
[TBL] [Abstract][Full Text] [Related]
7. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract][Full Text] [Related]
8. Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation.
Han W; Sfondouris ME; Jones FE
Biochem Biophys Rep; 2016 Sep; 7():323-327. PubMed ID: 28955922
[TBL] [Abstract][Full Text] [Related]
9. HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.
Göthlin Eremo A; Tina E; Wegman P; Stål O; Fransén K; Fornander T; Wingren S
Int J Oncol; 2015 Oct; 47(4):1311-20. PubMed ID: 26238412
[TBL] [Abstract][Full Text] [Related]
10. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
Zhu Y; Sullivan LL; Nair SS; Williams CC; Pandey AK; Marrero L; Vadlamudi RK; Jones FE
Cancer Res; 2006 Aug; 66(16):7991-8. PubMed ID: 16912174
[TBL] [Abstract][Full Text] [Related]
11. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines.
Salami S; Karami-Tehrani F
Clin Biochem; 2003 Jun; 36(4):247-53. PubMed ID: 12810152
[TBL] [Abstract][Full Text] [Related]
12. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
13. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
14. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
16. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
19. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
Zheng Y; Sowers JY; Houston KD
Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
[TBL] [Abstract][Full Text] [Related]
20. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
